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Improvement in left ventricular ejection fraction is a measure of 
salvage of ischemic myocardium after reperfusion therapy for 
acute myocardial infarction. The degree of improvement in left 
ventricular ejection fraction may be influenced by many factors. 
Therefore, 137 patients in whom paired radionuclide angiograms 
were obtained within 24 h of acute infarction and before hospital 
discharge were retrospectively evaluated to determine which 
factors most affect improvement in ejection fraction. Only base-
line ejection fraction correlated significantly with improvement in 
ejection fraction by both univariate analysis (ejection fraction as a 
continuous variable, p < 0.001; ejection fraction as a categorical 
variable, ~45% versus >45%, p < 0.0001) and multivariate 
analysis (p < 0.0001). 
Reperfusion status (patent versus occluded infarct artery) and 
Thrombolytic therapy has been shown to reduce mortality 
due to acute myocardial infarction 0-6). It has also been 
shown to limit infarct size (7-10). Consequently, the primary 
mechanism for prevention of death is believed to be salvage 
of ischemic myocardium. Global left ventricular ejection 
fraction is believed to be an indirect indicator of infarct size 
and has been proposed as a surrogate end point since 
improvement in this variable would reflect salvage of isch-
emic myocardium. A surrogate end point for thrombolytic 
trials that reflect mortality is needed as mortality decreases 
to approximately 5% and new therapies require testing. The 
sensitivity and appropriateness of the ejection fraction as a 
surrogate end point for clinical trials is being questioned 
because of the frequently observed paradox of a reduction in 
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extent of coronary artery disease (one, two or three vessel) were 
significant factors by multivariate but not by univariate analysis. 
Location of infarction, treatment modality and time to treatment 
did not correlate with change in ejection fraction by either 
statistical technique. 
Thus, of those factors tested, baseline left ventricular ejection 
fraction is the most potent predictor of improvement in ventricu-
lar function after acute infarction. Knowledge of baseline ejection 
fraction may be helpful in deciding whether to treat some patients 
with equivocal indications or contraindications for reperfusion 
therapy. Clinical trials of reperfusion strategies should stratify 
patients on the basis of baseline ejection fraction if ejection 
fraction is to be used as an end point for myocardial salvage. 
(J Am Coll CardioI1991;17:613-20) 
mortality without a noticeable change in ejection fraction 
(11). 
Previous studies (12-16) suggest that baseline ejection 
fraction measured soon after hospital admission is helpful in 
identifying those patients who will benefit most from reper-
fusion therapy. However, the importance of baseline ejec-
tion fraction relative to other factors believed to be respon-
sible for improvement after reperfusion is not known. If the 
relative order of importance of such factors were known, 
two goals could be met: I) Patients most likely to respond to 
aggressive intervention would be identified, and 2) these 
results could guide the design of future trials. 
Methods 
Patient identification. Three hundred twenty-two patients 
with acute myocardial infarction characterized by electro-
cardiographic (ECG) ST segment elevation and subse-
quently confirmed by characteristic creatine kinase MB 
isoenzyme elevation presented to The Methodist Hospital, 
Houston, Texas between December 1981 and July 1987. 
During this period, patients were treated with one of four 
modes of therapy: pharmacologic thrombolysis using strep-
tokinase or recombinant tissue-type plasminogen activator 
(rt-PA), direct percutaneous transluminal coronary angio-
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plasty, combined thrombolysis and coronary angioplasty or 
conventional therapy (neither thrombolytic therapy nor cor-
onaryangioplasty). 
In 142 patients paired radionuclide angiograms were 
obtained within the 1st 24 h and again before discharge at 
day 10; these patients are the subjects of this study. Four 
patients (each in the conventionally treated group) did not 
undergo coronary arteriography. Clinical data were incom-
plete in one other patient. Consequently, reperfusion status, 
the infarct-related coronary vessel and the number of dis-
eased vessels could be assessed in 137 patients, who consti-
tute the study group. 
All treatment given to and studies performed on patients 
included in the study were done as part of protocols of 
reperfusion studies approved by the Institutional Review 
Board of Baylor College of Medicine and The Methodist 
Hospital. 
Coronary arteriography and angioplasty. Cardiac cathe-
terization was performed a median of 6 h after the onset of 
symptoms. All patients received a 5,000 U intravenous bolus 
of heparin after arterial access was secured. Arteriograms 
were read retrospectively by two experienced angiogra-
phers. When the two angiographers did not agree on a 
particular feature, a third angiographer was asked to resolve 
the dispute. Coronary artery lesions were classified using the 
Coronary Artery Surgery Study (CASS) classification (17) 
for both lesion location and number of vessels diseased. 
Occluded vessels were identified as those with Thrombolysis 
in Myocardial Infarction (TIMI) grade 0 or I flow, while 
patency was defined as TIMI grade II or III flow (18). The 
infarct-related coronary artery was identified using ECG 
criteria (19) and wall motion abnormalities. Percutaneous 
transluminal coronary angioplasty was performed in most 
cases with an over the wire technique. 
Radionuclide ventriculography. Gated blood pool radio-
nuclide angiography was performed within 24 h of admission 
using an in vivo or in vitro red blood cell labeling technique 
with 25 to 30 mCi of technetium-99m. Images were acquired 
on a small field of view portable single crystal gamma camera 
coupled with a general purpose collimator. The camera's 
energy discriminator was set at 140 ke V with a 20% window. 
Images were obtained at rest and ejection fraction was 
calculated in the left anterior oblique view that allowed the 
best septal delineation. Images were acquired for 180 sand 
contained 16 to 32 frames/cardiac cycle. 
Left ventricular ejection fraction was calculated by a 
standard method in our laboratory (20). Change in ejection 
fraction, measured in absolute ejection fraction units, was 
calculated by using admission and predischarge radionuclide 
ventriculograms (predischarge minus admission). All radio-
nuclide ventriculograms were obtained and interpreted by 
the same laboratory. 
Statistical analysis. The relation of two categorical varia-
bles (for example, study group and gender in Table 1) was 
analyzed using the chi-square test (21). The relation of two 
continuous variables (such as change in ejection fraction and 
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age in Table 2) was analyzed using the correlation coefficient 
(22). The relation of a continuous variable with a categorical 
variable (such as change in ejection fraction and location of 
myocardial infarction in Table 3) was analyzed using one 
way analysis of variance or its nonparametric equivalent, the 
Kruskal-Wallis test (21). Two variables, baseline ejection 
fraction and time to treatment, were analyzed as both 
categorical (Table 3) and continuous (Table 2) variables. The 
Bonferroni procedure was used to adjust the level of statis-
tical significance when mUltiple variables were tested (22). 
Table 1 shows 15 variables tested; hence a statistically 
significant p value was considered to be 0.003 (0.05 -:- 15). In 
Tables 2 and 3, 11 variables were compared with change in 
ejection fraction; thus, the p value of significance was 0.005 
(0.05 -:- 11). 
The relative independent contribution to the change in 
ejection fraction of various clinical factors was assessed 
using multivariate analysis. Because most of the clinical 
variables were categorical, a stepwise logistic regression 
model (BMDP program LR) was used (23). This model 
requires that the dependent variable be categorical. Because 
a change in ejection fraction of 2:5 ejection fraction units on 
repeat radionuclide angiographic studies is considered to be 
beyond the variability of the technique (20), the dependent 
variable was dichotomized at this value. Variables that were 
either significant or of borderline significance by univariate 
analysis were entered into the model. 
Results 
Baseline characteristics of study group compared with 
those of other patients with infarction (Table 1). The mean 
age of the 137 patients was 56 years (range 25 to 78). There 
were 112 men (82%) and 25 women (18%). Fifty-three 
patients (39%) were treated with a combination of angio-
plasty and thrombolytic therapy (intravenous streptokinase, 
n = 8; intracoronary streptokinase, n = 14; intravenous 
rt-PA, n = 31). Forty-seven patients (34%) were treated with 
thrombolysis alone (intravenous streptokinase, n = 13; 
intracoronary streptokinase, n = 16; intravenous rt-PA, n = 
18). Eighteen patients (13%) were treated with percutaneous 
coronary angioplasty alone, and 19 (14%) with conventional 
medical treatment as part of the control group in an earlier 
trial of intracoronary streptokinase (14). Pertinent clinical 
characteristics, including extent of coronary artery disease, 
patency of infarct artery, infarct location, risk factors and 
hospital course are shown in Table 1. 
To determine if the study group was representative of 
patients with myocardial infarction treated at our institution, 
these features were compared with those in the 180 patients 
who were initially screened but were excluded from the 
study because they did not have paired radionuclide ventric-
ulograms. The only statistically significant difference was in 
treatment mode: the study group had a higher frequency of 
combined coronary angioplasty plus thrombolysis and 
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Table 1. Characteristics of Study Group Compared With Those of Patients With Acute Myocardial Infarction 
Nonstudy 
Study Group Patients p 
(n = 137) (n = 180) Value Test 
Age (yr) 56 ± 11 57 ± 10 0.3 Kruskal-Wallis 
Gender 
Men 112 (82%) 135 (75%) 0.15 Chi-square 
Women 25 (18%) 45 (25%) 
Risk factors Chi-square 
Smoking history 101 (74%) 117 (67%) 0.17 
Hypertension 59 (43%) 79 (45%) 0.78 
Hyperlipidemia 26 (19%) 41 (23%) 0.36 
Diabetes 19 (14%) 32 (19%) 0.31 
Family history 64 (47%) 85 (48%) 0.78 
Location of infarction 0.46 Chi-square 
Anterior 72 (53%) 87 (48%) 
Inferior 65 (47%) 93 (52%) 
Extent of CAD 0.27 Chi-square 
1 vessel 46 (34%) 73 (43%) 
2 vessel 51 (37%) 57 (34%) 
3 vessel or left main 40 (29%) 39 (23%) 
Patency of infarct artery 0.14 Chi-square 
Patent 98 (72%) 104 (62%) 
Occluded 39 (28%) 64 (38%) 
Hospital course Chi-square 
Bypass surgery 24 (18%) 21 (12%) 0.14 
Death 4 (3%) 15 (8%) 0.04 
Time (hr) to treatment 4.5 (n = 118) 4.8 (n = 128) 0.47 Kruskal-Wallis 
(median) 
Peak creatine kinase 1932 ± 1795 1580 ± 1651 0.01 Kruskal-Wallis 
(mean) 
Treatment modality 0.0005' Chi-square 
PTCA + thrombolysis 53 (39%) 43 (24%) 
PTCA only 18 (13%) 40 (22%) 
Thrombolysis only 47 (34%) 45 (25%) 
Conventional 19 (14%) 52 (29%) 
'Using the Bonferroni procedure, 0.003 (0.05 -;- 15) is statistically significant. CAD = coronary artery disease; PTCA = percutaneous transluminal coronary 
angioplasty. 
thrombolysis only and a lower frequency of angioplasty only 
and conventional therapy. 
Concomitant medication administered during the hospi-
tal stay included nitroglycerin (64%), beta-adrenergic block-
ers (15%) and calcium channel blockers (35%), and did not 
differ statistically between patients with and without paired 
radio nuclide ventriculograms. 
Table 2. Correlation of Pertinent Continuous Variables to Change 
in Ejection Fraction by Univariate Analysis 
p 
Variable n Value 
Baseline EF 137 -0.3913 <0.001* 
Age 137 -0.1789 0.01 
Time to treatment 118 -0.0244 0.20 
Peak CK 137 0.1213 0.04 
*U sing the Bonferroni procedure, 0.004 (0.05 -;- 11 variables used in 
Tables 2 and 3) is statistically significant. CK = serum creatine kinase; EF = 
ejection fraction. 
Effect of Clinical Variables on Improvement in 
Left Ventricular Function: Univariate Analysis 
Baseline ejection fraction (Tables 2 and 3). There was an 
inverse linear relation between baseline ejection fraction and 
change in ejection fraction (r = -0.3913, P < 0.001). The 
mean baseline global ejection fraction for the 137 patients 
was 45.7% and the mean predischarge ejection fraction was 
49.6%. Because an ejection fraction of 45% is a value below 
which patients are clearly considered to have left ventricular 
dysfunction, the patients were separated into two groups: 
those with a baseline ejection fraction ~:::45% (n = 64) and 
those with an ejection fraction >45% (n = 73). The mean 
change in ejection fraction of those patients whose baseline 
ejection fraction was :545% differed significantly from those 
whose baseline ejection fraction was >45% (7.9 ± 10.1% 
versus 0.4 ± 8.3%, p < 0.0001) (Table 3). Forty (63%) of 64 
patients with a baseline ejection fraction :545% had a ::::5 unit 
improvement in ejection fraction, whereas only 21 (29%) of 
73 patients with an ejection fraction >45% had this degree of 
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Table 3. Descriptive Statistics for Baseline. Predischarge and Change in Ejection Fraction and the Effect of Pertinent Categorical 
Variables on Change in Ejection Fraction by Univariate Analysis 
n Baseline EF (%) Predischarge EF (%) dEF(%) p Value' 
Baseline EF O.OOOlt 
,,;45% 64 34.3 ± 7.8 42.1 ± 12.9 7.9 ± 10.1 
>45% 73 55.7 ± 6.8 56.1±8.5 0.4 ± 8.3 
Reperfusion status 0.01 
Patent 98 44.7 ± 12.6 49.8 ± 12.7 5.1 ± 10.4 
Occluded 39 48.0 ± 13.6 48.9 ± 13.4 0.9 ± 7.9 
Extent of CAD 0.29 
I vessel 46 45.0 ± 12.3 51.3 ± 11.8 6.3 ± 11.5 
2 vessel 51 48.5 ± 12.6 51.4 ± 12.6 3.0 ± 10.5 
3 vessel 40 42.9 ± 13.7 45.2 ± 13.0 2.3 ± 6.1 
Infarct location 0.12 
Anterior 72 39.7 ± 11.4 44.8 ± 13.2 5.1 ± 10.3 
Inferior 65 52.3 ± 11.3 54.8 ± 10.2 2.5 ± 9.3 
Treatment modality 0.23 
PTCA + lysis 53 43.7 ± 12.7 49.2 ± 13.0 5.5 ± 9.9 
PTCA only 18 46.2 ± 12.6 51.6 ± 9.9 5.4 ± 6.6 
Lysis only 47 45.2 ± 13.9 47.4 ± 14.0 2.2 ± 11.7 
Conventional 19 51.3 ± 9.9 53.9 ± 11.1 2.1 ± 6.5 
Time to treatment 0.28 
,,;4 h 54 43.7 ± 12.5 48.6 ± 13.2 4.9 ± 10.7 
>4 h 64 45.4 ± 13.7 49.0 ± 13.0 3.6 ± 10.1 
Gender 0.53 
Male 112 44.9 ± 13.2 48.5 ± 13.0 3.6 ± 10.1 
Female 25 49.2 ± 11.4 54.4 ± 11.3 5.3 ± 8.8 
*p value from the comparison of differences of change in EF among the subgroups for each variable. All variables in this table were analyzed by the 
Kruskal-Wallis test. tBased on the Bonferroni procedure. a p value of 0.004 (0.05 ~ II) is considered statistically significant. since 11 variables were tested against 
change in EF. Abbreviations as in Tables I and 2. 
improvement (p < 0.(01). The baseline ejection fraction of 
the 61 patients whose ejection fraction increased 2::5 units 
was 41.0 ± 11.2%, compared with 49.4 ± 13.1% for the 76 
whose ejection fraction increased <5 units (p = 0.0001). 
Among the 73 patients with baseline ejection fraction 
>45%, the change in ejection fraction differed significantly 
between those (n = 41) with mild compromise (ejection 
fraction >45 to :555%) and those (n = 32) with an ejection 
fraction >55% (2.9% ± 7.7% versus -2.9% ± 7.9%, respec-
tively; p = 0.003). A 2::5 unit improvement in ejection 
fraction occurred more frequently in the former group than 
in the latter (41% versus 13%, p = 0.007). Moreover, in 23 
(70%) of 32 patients with a baseline ejection fraction >55% 
no improvement could be detected (that is, change in ejec-
tion fraction :50). 
Reperfusion status (Table 3). Reperfusion of the infarct-
related artery occurred in 98 (72%) of the 137 patients, 
including five of the 24 conservatively treated patients. Their 
ejection fraction improved significantly, from 44.7% to 
49.8% (p < 0.0001). In the 39 patients with a persistently 
occluded artery ejection fraction did not increase signifi-
cantly. The change in ejection fraction for patients with a 
reperfused infarct artery was greater than that for those with 
an occluded artery (5.1% versus 0.9%, p = 0.01). However, 
after correction according to the Bonferroni procedure, the 
difference did not reach the significance level. Of the 61 
patients with an improvement in ejection fraction of 2::5 
units, 51 (84%) had a successfully reperfused artery and only 
10 (16%) had an occluded artery. 
Forty-nine (50%) of the 98 patients with successful reper-
fusion had a baseline ejection fraction of :545%. The degree 
of improvement in ejection fraction among these patients 
was significantly greater than among those with a baseline 
ejection fraction >45% (9.0 ± 10.3% versus 1.2 ± 8.9%, p < 
0.0(01). Among the 39 patients whose infarct-related artery 
could not be reperfused, the 15 with a baseline ejection 
fraction of 45% had more improvement in ejection fraction 
than the 24 with a baseline ejection fraction >45% (4.2 ± 
8.7% versus -1.2 ± 6.6%, respectively, p < 0.015). An 
increase of 2::5 ejection fraction units occurred in 5 (33%) of 
the 15 patients in whom reperfusion was unsuccessful and 
baseline ejection fraction was 45%. 
Extent of coronary artery disease (Table 3). In patients 
with one vessel disease ejection fraction increased from 45% 
to 51.3% (p = 0.006); in patients with two and three vessel 
disease it did not improve significantly. However, the 
change in ejection fraction between groups was not signifi-
cantly different (6.3% versus 3% versus 2.3%, p = 0.29). 
Fifty-seven percent of patients with one vessel disease had a 
change in ejection fraction of 2::5% compared with 41 % of 
patients with two vessel disease and 35% of patients with 
three vessel disease (p = 0.11). 
Location of myocardial infarction (Table 3). In patients 
with anterior infarction ejection fraction improved from 
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Table 4. Coding for the Variables in the Final Model of the 
Logistic Regression 
Variable 
Change in EF 
Baseline EF 
Reperfusion status 
Extent of CAD' 
Measurement 
1 = <5 units 
o = ~5 units 
Percent 
-1 = patent 
1 = occluded 
1 vessel: 
2 vessels: 
3 vessels: 
no. of vessels (a) = -1 
no. of vessels (b) = -1 
no. of vessels (a) = 1 
no. of vessels (b) = 0 
no. of vessels (a) = 0 
no. of vessels (b) = 1 
'Because there are three possible categories for extent of coronary artery 
disease. it takes two dummy variables to uniquely define the categories. 
number of vessels (a) and number of vessels (b). Abbreviations as in Tables 1 
and 2. 
39.7% at baseline to 44.8% before discharge (p = 0.000l). 
Patients with inferior infarction had a higher baseline ejec-
tion fraction (52.3%, p < 0.001) than did those with anterior 
infarction. The comparison of anterior and inferior infarct 
locations with respect to change in ejection fraction from 
baseline to before discharge was not significantly different 
(5.1% versus 2.5%, p = 0.12). However, ejection fraction 
varied greatly among patients with inferior myocardial in-
farction; 16 (25%) had a baseline ejection fraction ::s45%. 
The degree of ejection fraction improvement in this sub-
group was significant (10.1 ± 9.6%, p = 0.0008). 
Treatment modality (Table 3). Patients assigned to dif-
ferent treatment modes or conventional treatment did not 
differ with respect to baseline ejection fraction, predischarge 
ejection fraction or change in ejection fraction. Among 
treatment groups, the combined coronary angioplasty and 
thrombolysis group and the angioplasty only group had a 
significant improvement in ejection fraction from baseline to 
predischarge. 
Time to treatment (Tables 2 and 3). There was no signif-
icant correlation between time from the onset of symptoms 
to initiation of treatment and change in ejection fraction (r = 
-0.0244; p = 0.20). Further, when times to treatment were 
dichotomized at 4 and 6 h windows, which are widely used in 
clinical trials and clinical practice, change in ejection frac-
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tion was not significantly different between groups (p = 0.28 
and 0.58, respectively). 
Other variables (Table 2). Neither age nor peak creatine 
kinase level correlated significantly with change in ejection 
fraction. 
Multivariate analysis (Table 4). Stepwise logistic regres-
sion was used with the change in ejection fraction «5, 2::5) 
as the dependent variable. The independent variables in-
cluded the continuous variables of age, baseline ejection 
fraction and peak creatine kinase, and the categorical vari-
ables of infarct -related artery, infarct location, treatment 
mode, reperfusion status, gender and the number of arteries 
involved. The final equation contained the variables: base-
line ejection fraction, reperfusion status and number of 
arteries involved. The Hosmer-Lemeshow (23) goodness of 
fit test indicated that the fit was acceptable (chi square = 
5.273, degrees of freedom = 8, p = 0.728). If we let p equal 
the probability that the change in ejection fraction is 2::5, the 
logistic regression equation is: In [p/O - p)] = 2.1633 -
0.0587 baseline ejection fraction - 0.4866 reperfusion status 
+ 0.1255 number of vessels (a) - 0.5411 number of vessels 
(b). 
Significant variables. The coding for these variables is 
given in Table 4 and the coefficients, standard errors and 
significance of the individual coefficients for the logistic 
regression model are shown in Table 5. The interpretation of 
the equation is that the lower the baseline ejection fraction, 
the higher the probability that the change in ejection fraction 
is 2::5 units; that patients with a patent infarct-related artery 
have a higher probability of a change of 2::5 units than do 
those with an occluded artery; and that the fewer vessels 
that are diseased the higher the probability that the change in 
ejection fraction will be 2::5 units. 
Discussion 
Factors affecting improvement in left ventricular function. 
The purpose of this study was to examine the relative 
importance of other factors believed to be responsible for 
improvement in left ventricular function after reperfusion 
therapy. Our principal finding was that baseline ejection 
fraction is the most potent predictor of improvement in 
ejection fraction. In fact, it was the only clinical variable to 
Table 5. Coefficients. Standard Errors and Significance of the Individual Coefficients for the 
Logistic Regression Model 
Name of Variable Coefficient SE Chi-Square DF p Value 
Baseline EF -0.0587 0.0162 15.00 0.0001 
Reperfusion status -0.4866 0.2268 4.85 0.0276 
Extent of CAD 
(a) 0.1255 0.2674 3.96 2 0.1377 
(b) -0.5411 0.2925 
Constant 2.1633 0.7508 8.97 0.0027 
DF = degree of freedom; SE = standard error; other abbreviations as in Tables 1. 2 and 4. 
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predict improvement by both univariate and multivariate 
analysis. Improvement was greatest in patients with the 
most severely depressed left ventricular ejection fraction 
followed by those with modest left ventricular dysfunction; 
improvement could not be demonstrated in those with an 
initially preserved ejection fraction. As expected, additional 
factors played a role in the recovery of ventricular function: 
the presence or absence of reperfusion and the extent of 
coronary artery disease were each significant using multi-
variate analysis. Other investigators (12-16) have reported 
that baseline ejection fraction is a major determinant of the 
degree of recovery of left ventricular function. However, our 
findings are unique, in showing the superiority of baseline 
ejection fraction over those other factors in affecting im-
provement in ejection fraction. Additionally, even within 
subgroups such as those who had reperfusion and those who 
did not, baseline ejection fraction further influenced the 
change in ejection fraction. 
Reperfusion status also appeared to be a factor in the 
change in ejection fraction. Although reperfusion status was 
of equivocal statistical significance by univariate analysis 
when corrected by the Bonferroni procedure, it was a 
statistically significant factor by multivariate analysis. This 
observation is in agreement with the multitude of other 
reports citing successful reperfusion as a contributor to 
improvement in left ventricular function (7,9,10,14,24-28). 
Multivariate analysis showed the extent of coronary 
artery disease to be a factor in the recovery of left ventric-
ular function after infarction; patients with one vessel dis-
ease were more likely to have an improved ejection fraction. 
Because patients with acute infarction and one vessel dis-
ease are more likely to have a higher baseline ejection 
fraction than are those with multivessel disease, the obser-
vation that the ejection fraction in patients with one vessel 
disease is more likely to increase at first seems incongruous 
with our finding that a low baseline ejection fraction is the 
most important determinant of improvement in ejection 
fraction. However, because improvement in global ejection 
fraction after infarction is principally a reflection of improve-
ment in regional function of the infarct zone (27), it is 
possible that infarct zone function in patients with one vessel 
disease is more likely to improve because of better collateral 
flow to the infarct zone through nondiseased vessels. Several 
studies (29-31) involving coronary angiography during the 
acute phase of myocardial infarction show improved ejection 
fraction in patients with, as opposed to those without, 
angiographically visible collateral vessels. 
Factors that did not affect left ventricular function. In our 
study, time to treatment was not an independent predictor of 
recovery of left ventricular function. This observation seems 
to contradict results obtained in animal models of myocar-
dial infarction and reperfusion (32,33), but reflects a paradox 
recently borne out by several large prospective clinical trials 
and commentaries (11,30,34). We suspect that this apparent 
discrepancy relates to difficulties inherent in timing the onset 
of acute infarction in humans, the presence of spontaneous 
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reperfusion and reocclusion, as well as the presence of 
collateral flow to the infarct zone. Other variables, such as 
age, gender, location of infarction, treatment modality and 
infarct vessel, were not independently correlated with 
change in ejection fraction. 
Limitations of this study. The limitations of a retrospec-
tive analysis such as ours must be acknowledged before 
conclusions can be drawn. First, because of the diversity of 
patients included in this study and the lack of a trial design in 
which treatment modes are randomly assigned, no conclu-
sion can be drawn concerning the efficacy of different 
therapeutic strategies. Second, although coronary arterio-
grams were usually obtained within hours of infarction, the 
timing of arteriographic studies was variable. Hence, data 
relative to reperfusion status are not standardized to a given 
point in time (for example, 90 min). Third, reocclusion of a 
reperfused vessel, which is likely to affect change in ejection 
fraction, cannot be reliably identified retrospectively. 
Fourth, ejection fraction may continue to improve after the 
time of hospital discharge (27,28). Hence, our findings can 
only be applied to changes in left ventricular function that 
occur early after infarction. Nevertheless, one recent study 
(35) shows that early improvement predicts both late im-
provement and late mortality. 
Finally, use of global ejection fraction as an end point 
suffers from the limitation that this variable is load depen-
dent and that its use may obscure regional function, which 
has been shown to be a more sensitive index of myocardial 
salvage (36,37). Nonetheless, global ejection fraction is the 
most frequently and conveniently measured index of infarct 
size and, of all variables, has been shown to correlate the 
most closely with intermediate and long-term mortality rates 
after myocardial infarction (35,38,39). Despite these limita-
tions, our analysis permits several important conclusions 
concerning a population representative of patients consid-
ered for reperfusion therapy. 
Implications for planning and interpreting prospective 
studies. Although our findings may seem tautologic (that is, 
patients with low ejection fraction show the most improve-
ment only because they have the most room for improve-
ment), they raise major implications for planning and inter-
preting prospective studies. In this regard, three large, 
randomized, prospective studies (40-42) that tested reper-
fusion strategies with rt-PA and percutaneous coronary 
angioplasty did not show significant benefit of a particular 
reperfusion strategy. These trials had patients with a higher 
baseline ejection fraction (50%, 53% and 51%, respectively) 
than that of our patients. Only one of these trials (44) 
included a prospectively defined group likely to have a lower 
ejection fraction. Furthermore, a recent trial (43) comparing 
the effects of streptokinase and rt -P A on global ejection 
fraction studied two groups in which each had a final mean 
ejection fraction of 58%. In any of these studies the expected 
improvement in ejection fraction would be small and there-
fore differences between the groups would be difficult to 
detect. If ejection fraction is to be used as an end point in 
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reperlusion studies, our results indicate either that patients 
should be prestratified according to baseline left ventricular 
function or that such trials should be limited to patients with 
a clinically large infarction and reduced baseline ejection 
fraction. 
Furthermore, the finding that baseline left ventricular 
ejection fraction is an even more potent independent predic-
tor of subsequent improvement in ventricular function than 
is reperlusion status calls into question use of global ejection 
fraction as an end point in the study of strategies of reper-
fusion. This is particularly true in an age when reperlusion 
trials of acute myocardial infarction are unlikely to include a 
true placebo group. Therefore, it appears that ejection 
fraction alone should not be used as a measure of the success 
of reperlusion therapy because factors other than reperlu-
sion alone contribute to its increase. 
Clinical implications. Although our findings might at first 
glance be interpreted to suggest that patients with preserved 
ventricular function should not receive reperlusion therapy 
for acute myocardial infarction, we do not believe this to be 
the case. There may be significant clinical advantages to 
reperlusion in this patient group. Compensatory hyperkine-
sia in non infarct zones may mask the degree of myocardium 
in jeopardy during acute infarction. Global ejection fraction 
may be normal despite significant regional dysfunction in the 
infarct zone. Reperlusion may improve regional function 
even though no net change in left ventricular ejection frac-
tion is seen. Additionally, establishing a patent vessel may 
lessen demand for collateral supply from a noninfarct -related 
artery, may reduce ischemia-induced ventricular arrhyth-
mias, and may lessen the likelihood of mechanical compli-
cations such as papillary muscle dysfunction or myocardial 
and septal rupture, even in those patients with preserved 
global function. 
Nevertheless, because the degree of myocardial salvage 
appears to be greater in patients with depressed ventricular 
function, knowledge of baseline ejection fraction may be 
useful in deciding whether to treat a patient who has mar-
ginal indications for or relative contraindications to reperfu-
sion therapy. Knowledge of baseline ejection fraction and, 
hence, expectations of benefit may be factored into the 
decision. This approach would be most useful in patients in 
whom ventricular function can be assessed rapidly. For 
these reasons, the routine availability of echocardiography 
in an emergency room or coronary care unit may have a 
place in triage of patients with acute myocardial infarction. 
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